1. Background
1.1 Background and challenges in the treatment of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumour and the third leading cause of cancer-related deaths worldwide, with more than 626,000 new cases each year. As a region with high incidence of hepatocellular carcinoma, China has as many as 390,000 deaths due to hepatocellular carcinoma each year, and hepatocellular carcinoma ranks the second most lethal malignant tumour in China. About 7080% of liver cancer patients are already in the middle or late stage when they are found, losing the chance of surgery. Especially in the advanced stage, it is often combined with distant metastases (such as lung, bone, abdominal cavity or lymph nodes, etc.), which makes the treatment very tricky and the prognosis extremely poor.
The strong drug resistance of liver cancer is the main reason limiting the application of chemotherapy. For many years, there has been no breakthrough progress in chemotherapy regimen and efficacy of liver cancer. FOLFOX4 regimen (oxaliplatin + calcium folinate + fluorouracil), as a standard chemotherapy regimen for advanced liver cancer, has an objective remission rate of only 9.1%, and a median survival time of only 10.7 months. Although targeted and immunotherapy have been the first choice for distant metastases in advanced hepatocellular carcinoma in recent years, the efficiency is low and most patients are insensitive to targeted and immunotherapy. Therefore, the development of new strategies that can overcome chemotherapy resistance and improve therapeutic efficacy is an urgent need in the treatment of advanced hepatocellular carcinoma.
1.2 ATRA
Alltrans retinoic acid (ATRA), as an active metabolite of vitamin A, was pioneered by a team of Chinese scientists, academician Wang Zhenyi, in the treatment of acute promyelocytic leukaemia (APL) in the 1980s, making APL the first type of leukaemia that can be treated by induced differentiation, and the five-year survival rate of patients increased from less than 20% to more than 90%, creating a miracle in the history of cancer treatment.
With further research, ATRA has also shown potential value in the treatment of many solid tumours.
| Type of cancer | Treatment programme | Mechanism of action | Clinical effectiveness | Level of evidence |
|---|---|---|---|---|
| Acute promyelocytic leukaemia | ATRA alone or in combination with arsenic | Induction of differentiation, degradation of PMLRARα fusion protein | 5-year survival rate >90 per cent | Clinical standard treatment |
| pancreatic | ATRA combination chemotherapy | Reversing Vitamin A Deficiency | Median OS extended to 10.9 months | Phase III clinical trials |
| liver cancer | ATRA Joint FOLFOX4 | Induction of differentiation and reduction of chemoresistance | Median OS extended to 16.2 months | Phase III clinical trials |
| Radiotherapy for solid tumours | ATRA combined with radiotherapy | Macrophage polarisation, enhanced T-cell infiltration | 92% reduction in tumour size | Preclinical studies |
1.3 Feasibility of ATRA in the treatment of hepatocellular carcinoma
ATRA has diversified mechanisms of action in liver cancer treatment, which can induce the differentiation of tumour stem cells, activate the RAR/RXR signalling pathway, induce TICs to differentiate into mature liver cancer cells and lose their self-renewal ability, and at the same time down-regulate the expression of stem cell markers, such as EpCAM, CD133, and CD90, to improve the efficacy of the FOLFOX regimen; moreover, it has been found that ATRA in combination with chemotherapeutic drugs In addition, it was found that ATRA in combination with chemotherapeutic agents significantly inhibited AKT (Thr308) phosphorylation.Over-activation of the AKT signalling pathway is closely associated with hepatocellular carcinoma progression, drug resistance, and poor prognosis.ATRA, by inhibiting this pathway, reduced tumour cell viability and drug resistance, and promoted chemotherapy-induced apoptosis.
2. Research content
2.1 Construction of all-trans retinoic acid total synthesis pathway
Objective: build a de novo biosynthetic route that converts central metabolites into all-trans retinoic acid (ATRA) inside engineered bacteria. The pathway is split into an upstream carotenoid module and a downstream retinal/retinoic-acid module, enabling stepwise balancing and orthogonal control.
| Module | Gene(s) | Putative function in the route | Intended product |
|---|---|---|---|
| Upstream carotenoid module | crtE, crtB, crtI, crtY (as crtEBIY) | Terpenoid flow to β-carotene via GGPP → phytoene → lycopene → β-carotene | β-carotene |
| Downstream retinal / ATRA module | blh, raldh, IIdR | blh: β-carotene 15,15′-dioxygenase (β-carotene → retinal); raldh: aldehyde dehydrogenase (retinal → ATRA); IIdR: regulatory element to assist expression tuning and pathway balance | Retinal → ATRA |
Design principles: (i) modularization (separate plasmids for upstream and downstream steps to simplify optimization); (ii) strong-yet-tunable expression (trc promoter–driven cassettes); (iii) genomic integration (CRISPR–Cas9 assisted) for stability in production strains; and (iv) assayability through PCR, gel electrophoresis, colony PCR, and downstream metabolite readouts.
Planned workflow
- Assemble upstream β-carotene synthesis with the crtEBIY cassette to accumulate β-carotene as the direct precursor.
- Assemble downstream ATRA synthesis with blh and raldh, supported by IIdR for expression balance, converting β-carotene → retinal → ATRA.
- Balance flux by adjusting promoter/copy context (plasmid vs. genome) and culture parameters to minimize by-product formation and maximize ATRA.
- Verification by amplification/electrophoresis of each fragment and by metabolite analysis after induction.
Expected outcome: a complete, verifiable ATRA pathway that can be tuned at the module level and transferred into the final chassis for stable production and downstream testing.
2.2 Construction of ATRA engineering bacteria
Objective: create engineered strains that carry the two pathway modules on defined constructs (plasmid and/or genomic integration) for robust ATRA production and subsequent characterization.
Strain and construct strategy
- Host selection: laboratory E. coli for cloning and amplification; production strain with CRISPR-enabled genomic edits for stability.
- Upstream plasmid: pET-21a-trc–crtEBIY (β-carotene module).
- Downstream plasmid: pET-21a-trc–raldh-IIdR-blh (retinal/ATRA module).
- Genomic integration (as needed): CRISPR-Cas9–assisted knock-in of the downstream cassette to improve genetic stability and reduce plasmid burden.
Key implementation steps
- Fragment preparation: PCR amplification of crtEBIY, blh, raldh, and IIdR; agarose gel electrophoresis and gel recovery.
- Vector preparation: pET-21a-trc reverse PCR to open the expression frame (without lacI) for homologous recombination.
- One-step recombination: assemble upstream and downstream cassettes using C115 homologous recombinase.
- Transformation and screening: introduce constructs into E. coli Top10; select on appropriate antibiotics; verify by colony PCR.
- Optional genome editing: design sgRNA and donor fragments; perform CRISPR-Cas9–mediated integration; cure helper plasmids after verification.
- Expression tests: induce pathway modules, examine β-carotene accumulation and conversion to retinal/ATRA; iterate on promoter strength/copy number if needed.
Deliverables
- Validated plasmids: 21a-crtEBIY and 21a-raldh-IIdR-blh.
- Confirmed engineered strains for ATRA production (plasmid-borne and/or genome-integrated variants).
- Baseline production data for subsequent optimization in the experimental design section.
3. Experimental design
3.1 Basic experiments
3.1.1 Preparation of LB medium
[Experimental apparatus]
Electronic balance, autoclave, electric stove, medicine spoon, weighing paper, measuring cylinder, beaker, pH test paper, triangular flask, dropper
[Experimental reagents]
LB medium formula is shown in the table:
peptone 10 g; yeast powder 5 g; NaCl 10 g; agar 3 g/200 ml; deionised water to 1000 ml
[Experimental steps]
1. Accurately calculate and weigh the actual amount of each drug according to the recipe.
2. Use a measuring cylinder to weigh 1000 mL of tap water and pour it into a beaker. Then add each drug (except agar) to the beaker and stir to dissolve.
3. Adjust the pH to 7.2–7.6 with 1 mol/L HCl or 1 mol/L NaOH.
4. Dispense the prepared medium into triangular flasks to no more than 1/2 the height (100 mL of medium for a 250 mL triangular flask, 1.5 g of agar). If preparing solid or semi-solid media, place the weighed agar directly into the triangular flask. Cover with a rubber stopper.
5. Pack the flask with kraft paper, label, and sterilise at 121 °C for 30 min (total cycle ≤1 h 30 min including heat-up/cool-down). Take out the medium promptly after sterilisation and cool it down.
6. Store the sterilised and cooled medium in a cool room.
3.1.2 Plasmid extraction by kit
[Experimental reagents]
Plasmid extraction related reagents (Solution I, Solution II, Solution III, Buffer S, Wash Solution, Elution Buffer), anhydrous ethanol, ddH2O
[Laboratory equipment]
Pipette tips (blue, yellow), EP tube racks, EP tubes, adsorption columns, small centrifuges, micropipettes, thermostatic water baths, EZ-10 column plasmid extraction kits
[Experimental procedure]
1. Collect 1.5–5 ml overnight culture (OD600 ≥ 2.0), spin 12,000 rpm into 1.5 ml tubes, discard medium.
2. Add 250 μl Solution I, fully resuspend. (Ensure RNase A is added when first using Solution I.)
3. Add 250 μl Solution II along the wall, gently invert 5–10×, stand 2 min at RT. (Do not vortex.)
4. Add 250 μl Solution III, gently invert 5–10×. After white floc appears, stand 5 min, spin 12,000 rpm 10 min. Transfer supernatant, add 1/2 vol anhydrous ethanol, invert to mix. (If much starting material, stand 2 min to remove RNA.)
5. Prime EZ-10 Column with 200 μl Buffer S, stand 1 min, spin 8,000 rpm 1 min, discard flow-through. (Use within a day.)
6. Load solution from step 4 (≤750 μl per pass), stand 1 min, spin 8,000 rpm 2 min; repeat until finished.
7. Add 500 μl Wash Solution along the wall, or invert 2–3×, spin 10,000 rpm 1 min.
8. Repeat wash once.
9. Empty and spin 10,000 rpm 2 min to remove residual wash.
10. Air-dry column 10 min at RT or 50 °C 5 min to remove ethanol.
11. Elute with 50 μl Elution Buffer (60 °C), stand 2 min, spin 10,000 rpm 2 min.
12. Store plasmid at −20 °C or use.
3.1.3 PCR
[Experimental reagents]
10× PCR buffer, dNTPs, primers, DNA template, Pfu DNA polymerase, ddH2O
[Laboratory instruments]
PCR instrument, micropipettes, tips (blue/yellow), EP racks, EP tubes, mini-centrifuge
[Experimental steps]
Configure a 20 μl reaction: 10× Buffer (Mg2+) 2 μl; dNTPs 2 μl; each primer 1 μl; template 1 μl; polymerase 0.5 μl; ddH2O 12.5 μl.
Program: 95 °C 5 min; 95 °C 45 s; anneal at Tm 45 s; 72 °C X min (30 cycles); final 72 °C 10 min. (Pfu 600 bp/min; Taq/Ex Taq 1000 bp/min.)
Brief spin; start program.
3.1.4 Agarose gel electrophoresis
[Experimental apparatus]
Horizontal electrophoresis, tabletop centrifuge, UV transilluminator, micropipette, Erlenmeyer flask, microwave oven
[Experimental reagents]
Ethidium bromide (10 mg/mL), agarose, loading buffer, marker
[Experimental procedure]
1. Dissolve 1.0 g agarose in 100 ml 1× TAE by microwaving (use PPE).
2. Cool to 50–60 °C, add 2 μl EB, mix, pour into gel tray with comb (3–5 mm thick). Add 1× TAE to tank (level ≈1 mm above gel).
3. Mix 5 μl PCR product with 1 μl 6× loading buffer, load carefully (new tip each sample).
4. Run 110 V (>40 mA) until bromophenol blue is ~2 cm from the gel front.
5. Image on gel imager (limit UV exposure to protect fragments for gel extraction).
3.1.5 Gel Recovery
[Experimental apparatus]
Water bath, balance, high-speed centrifuge, float, 1.5 ml tubes, Thermo GeneJET Gel Extraction Kit (K0692), scalpel
[Experimental reagents]
Ethanol 96–100%, isopropanol, 3 M sodium acetate pH 5.2, kit buffers (binding/wash/elution)
[Experimental steps]
1. Excise target band with clean blade; minimise UV; record gel weight in pre-weighed tube.
2. Add binding solution 1:1 (v/w) to gel (2:1 if agarose >2%).
3. Dissolve at 50–60 °C for ~10 min; invert intermittently; ensure fully dissolved (yellow indicates optimal pH; if orange/purple add 10 μl 3 M NaOAc).
4. Optional: ≤500 bp add isopropanol 1:2 (v/v); >10 kb add water 1:2 (v/v).
5. Load ≤800 μl per spin to GeneJET column; spin; discard flow-through; repeat until finished (≤1 g agarose/column).
6. Optional: Add 100 μl binding solution; spin; discard.
7. Wash with 700 μl diluted wash; spin 1 min; discard.
8. Spin empty column 1 min to remove ethanol.
9. Elute with 20–50 μl elution buffer (pre-heat to 65 °C for >10 kb). Stand 1 min; spin 1 min.
10. Discard column; store DNA at −20 °C.
3.1.6 Transformation of E. coli Top10 by heat-excited receptor cells
[Experimental reagents]
LB liquid/solid media, antibiotic, 0.1 M CaCl2, 30% glycerol
[Experimental instruments]
Inoculation loop, plate reader, ice box, centrifuges, water bath, incubator, sterile flasks/plates, tubes, micropipettes, tips
[Experimental steps]
1. Pick a single colony and culture in LB at 37 °C, 220 rpm for 12–16 h.
2. Inoculate 1–2% into 20 ml LB; 37 °C, 220 rpm to OD620 0.2–0.3.
3. Chill, spin 3000 rpm 10 min on ice.
4. Resuspend in 15–20 ml pre-chilled 0.1 M CaCl2, stand 30 min.
5. Spin; discard supernatant.
6. Resuspend in 1 ml 0.1 M CaCl2 + 1 ml 30% glycerol; aliquot 200 μl; store −20 °C.
7. Thaw on ice; add plasmid; ice 30 min.
8. Heat-shock 42 °C 2 min; ice 3 min.
9. Recover with 800 μl LB at 37 °C for 1–2 h.
10. Spin briefly; plate on selective LB; 37 °C 12–16 h.
3.1.7 Preparation of electroshock receptor states
[Experimental materials]
Plates, plasmid, LB, 10% glycerol, antibiotics, tubes, 2 mm electroporation cuvettes
[Laboratory equipment]
Incubator, shaker, ice bath, centrifuges, water bath
[Experimental steps]
1. Inoculate a single colony into 50 ml LB; 37 °C, 220 rpm overnight.
2. Grow to OD600=0.5; chill on ice ≥15 min.
3. Spin 3000 g, 4 °C, 10 min; discard supernatant.
4. Wash with 30 ml ice-cold 10% glycerol; repeat twice (3000 g, 5 min, 4 °C).
5. Resuspend in 500 μl 10% glycerol; aliquot 100 μl to 1.5 ml tubes.
6. Add 100–200 ng plasmid (~10 μl); ice 10 min; pre-chill cuvette 5 min.
7. Electroporate (2.5 kV, 5 ms; two pulses).
8. Add 900 μl LB; recover 37 °C 1–2 h.
9. Spin 3000 rpm 2 min; resuspend 100 μl LB; plate on selective LB; 37 °C 16 h.
3.2 Engineering bacterial construction of downstream plasmid 21a-raldh-IIdR-blh
3.2.1 Amplification and electrophoretic verification of target gene raldh, IIdR, blh fragments
The amplification method is the same as that described in 3.1.2, and the electrophoresis method is the same as that described in 3.1.4.
Primer name Primer sequence 5′→3′
IIdR-F gaggggttttttgGGAATTCc
IIdR-R caggacccactagtatgattg
blh-F ctgggtaaaacaatcatactag
blh-R gtggtggtggtggtgcTCGAGCGGTT
raldh-F gtttaactttaagaaggag
raldh-R ggtgagaatgGAATTCCcaa
3.2.2 Gel recovery of target gene raldh, IIdR, blh fragments
The gel recovery method is the same as described in 3.1.3.
3.2.3 Kit extraction of pET-21a-trc plasmid
The plasmid extraction method is the same as described in 3.1.1.
3.2.4 Reverse PCR and electrophoretic verification of pET-21a-trc plasmid
[Purpose of experiment]
Reverse amplification of pET-21a-trc plasmid to obtain the expression frame without lacI, facilitating homologous recombination with the raldh-IIdR-blh fragment to construct recombinant plasmid 21a-blh-raldh-IIdR.
[Experimental materials]
pET-21a-trc plasmid
Primer name Primer sequence 5′→3′
ATRA plasmid anti-p primer 1 TTGAACTTGTCATatgtatatctccttcttaaagttaaacaaa
ATRA anti-p primer 2 CGTTCCGTAACCGCTCGAgcaccaccaccaccaccactg
[Experimental reagents]
ddH2O, 10× PCR buffer, dNTP, Pfu DNA polymerase
[Experimental apparatus]
Mini-centrifuge, PCR instrument, micropipettes, tips, EP tubes, racks, water bath
[Experimental procedure]
1. PCR as in 3.1.1.
2. De-templating system in 1.5 ml tube: ddH2O 7 μl; Q.Cut DpnI 1 μl; 10× Cut Buffer 2 μl; 21a reverse PCR product 0.5 μl.
3. Incubate 37 °C 1 h.
4. Inactivate at 70 °C 15 min.
5. Electrophoresis as in 3.1.4.
Reverse PCR of pET-21a-trc generated the lacI-free expression frame for recombination.
3.2.6 Construction of plasmid 21a-blh-raldh-IIdR using homologous recombination methods
[Aim of experiment]
Construct plasmid 21a-raldh-IIdR-blh using C115 homologous recombinase
Experimental materials
raldh, IIdR, blh gene fragments, linearised 21a plasmid fragments
[Experimental reagents]
ddH2O, C115 homologous recombinase
Experimental apparatus
EP tube, rack, PCR instrument, tips, micropipette, water bath
Experimental steps
Configure 30 μl reaction: Linearised 21a 12 μl; blh 1 μl; IIdR 1 μl; raldh 0.8 μl; ddH2O 0.2 μl; ClonExpress Ultra One-Step 15 μl. Incubate 50 °C 30 min.
3.2.7 Transformation of Top10 by heat-stimulated sensory state
The recombinant plasmid was transformed into E. coli Top10 to amplify the recombinant plasmid for subsequent experiments. Receptor preparation and transformation methods are the same as those shown in 3.1.5.
3.2.8 Colony PCR to verify expression
3.3 Engineering bacterial construction of upstream plasmid 21a-crtEBIY
3.3.1 Amplification and electrophoretic verification of the target gene crtEBIY fragment
Amplification method as described in 3.1.2, electrophoresis method as described in 3.1.4.
Primer name Primer sequence 5′→3′
Target gene primer 1 ctttaagaaggagatataTTCATGACGGTCTGCGC
Target gene primer 2 ggggttatgctagttattgcTTAACGATGAGTCGTCATAATGGC
3.3.2 Gel recovery of the target gene crtEBIY fragment
The gel recovery method is the same as described in 3.1.3.
3.3.3 Kit extraction of pET-21a-trc plasmid
Same as experiment 3.2.3
3.3.4 Reverse PCR and electrophoretic verification of pTrc99a-crtEBIYZ plasmid
Same as experiment 3.2.4
Primer name Primer sequence 5′→3′
β-carotene plasmid primer 1 GCGCAGACCGTCATGAAtatatctccttcttaaag
β-carotene plasmid primer 2 ttatgacgactcatcgttaaGCAATAACTAGCATAACCCCTTGG
3.3.5 Construct plasmid 21a-crtEBIY using homologous recombination method
As in experiment 3.2.6, the recombination system is as follows:
makings dosage
Linearised 21a plasmid fragment 2 μl; crtEBIY gene fragment 3 μl; ClonExpress Ultra One-Step 5 μl
3.3.6 Heat-stimulated sensory state transformation Top10
Same as experiment 3.2.6
3.3.7 Colony PCR to verify expression
3.4 Gene integration of downstream plasmids using the CRISPR-Cas9 system
3.4.1 Design of sgRNA and construction of pEcgRNA plasmid
[Aim of experiment]
Design and construction of sgRNA and pEcgRNA plasmids for targeted knockdown of endA in the EcN genome, in order to facilitate subsequent integration of the raldh-IIdR-blh cassette.
[Experimental Materials]
pEcgRNA, BsaI enzyme
[Experimental reagents]
ddH2O, G buffer, T4 ligase buffer, LB/Sm plates (50 μg/mL), 5 ml LB+Sm (50 μg/mL)
[Experimental apparatus]
Micropipettes, tips, EP tubes, racks, water bath, applicator, biosafety bench, incubator
Experimental steps
1. Design sgRNA (20 bp) on the target site with CHOPCHOP: cgtagagtgggaacacgtcg, PAM: CGG.
2. Digest ccdB with BsaI to linearise pEcgRNA (cohesive ends 5′-TAGT / 5′-AAAC). Digest 20 μl: pEcgRNA 3; BsaI 1; G buffer 2; ddH2O 14.
dsDNA (N20) ligation system (50 μl): ddH2O 35; N20-up 5; N20-dn 5; T4 ligase buffer 5.
3. 95 °C 5 min; cool down stepwise; 16 °C 10 min.
4. Dilute dsDNA 200×, ligate 1 μl dsDNA + 1 μl BsaI-linearised pEcgRNA at 16 °C for 1 h with T4 ligase.
5. Transform into Top10, plate on Sm (50 μg/mL), 37 °C overnight; pick colonies into 5 ml LB+Sm and culture 220 rpm 37 °C overnight; extract plasmid and verify by digestion next day.
3.4.2 Fusion PCR to obtain donor destination fragments
[Purpose of experiment]
Construction of recombinant vector pMD18T-Donor containing upstream and downstream homology arms of endA by fusion PCR method.
[Experimental materials]
pMD 18T vector
Primer name Primer sequence 5′→3′
endA-up-F aactctcttacacccagcgc
endA-up-R tctcgatcctctacggacaaataacggtacatcacttactccg
endA-down-F atatccggattggcgggcgcgaaagagctaacc
endA-down-R ttgcaatcttctgccactgct
[Experimental reagents]
T4 ligase, ddH2O, 10× ligase buffer
[Experimental apparatus]
Micropipette, water bath, balance, 1.5 ml tubes
[Experimental steps]
1. Colony PCR on EcN to amplify endA with its homology arms (PCR as 3.1.1).
2. Ligate with linearised pMD18-T using T4 ligase → pMD18-T-endA.
3. Use pMD18-T-endA as template; reverse-PCR with endA-up-R′/endA-down-F′ to linearise (method as 3.2.4).
4. Use pET-21a-trc-raldh-IIdR-blh (10× diluted) as template to PCR the trc-promoter expression frame (4318 bp).
5. Electrophoresis to verify the expression frame.
6. Gel recovery.
7. Homologous recombination (C115) between the linearised vector and the r-I-b expression frame → pMD18T-Donor (contains r-I-b and endA arms). Finally amplify Donor with endA-up-F′/endA-down-R′ (5289 bp) and verify by electrophoresis.
3.4.4 Preparation of EcN (pEcCas) electroshock receptor cells
The preparation method is the same as described in 3.1.7
3.4.5 Electroshock transformation of DNA fragments with pEcgRNA
The electroporation cuvette was pre-cooled on ice for 5–10 min, then 13 μl of DNA fragment (gene homologous recombination sequence) and 3 μl of pEcgRNA-gene-N20 were added to 200 μl of EcN electrocompetent cells, gently mixed and transferred to a sterile 2 mm cuvette for electroporation (2.5 kV, 5 ms, twice). Add 900 μl drug-free LB, recover 37 °C for 1–2 h, pellet, resuspend in 100 μl LB and plate on LB with Kan (25 μg/mL) + Sm (50 μg/mL), 37 °C overnight. Negative control: cells without L-arabinose induction.
3.4.6 Translator Elimination and Validation
Positive mutant colonies were PCR-checked with gene-up-F/gene-dn-R (wild-type EcN as negative control). Pick positives and culture in LB with 10 mM rhamnose and Kan, 37 °C, 220 rpm overnight; transfer to drug-free LB for 12 h; plate on sucrose LB (3 g/L) to isolate single colonies. Screen on LB, Kan-LB and Sm-LB. Single colonies that fail on Kan and Sm but grow on drug-free plates indicate successful knockout/integration and loss of pEcgRNA-gene-N20 and pEcCas.
3.3 Experimental Results
3.3.1 Integration of Lactic Acid-Targeting Protein Gene
Acquisition and verification of OmpT donor and related fragments
Verification of etlpC gene integration
Expression and functional verification
Visible turbidity around 0.1 mol/L lactic-acid filter paper; absent near the negative control.
Virtual Experiments · Demo Videos
A selection of virtual experiment demonstrations for education and public outreach.
Online Molecular Biology Experiment Animation Simulation System
Interactive web platform for demonstrating molecular-biology procedures with step-by-step animations. Suitable for education and public outreach (no lab setup required).
Link: https://experiment-platform-ulp2vhzlm7xcpyh3bp2rvw.streamlit.app/